Novartis, Columbus et al. in €37.5m series-A round for Vivet

Other investors in the round included Roche Venture Fund, HealthCap, Kurma Partners and Ysios Capital.

The funds will be used by Vivet to keep developing its pipeline of gene therapy programmes targeting rare, inherited metabolic diseases, including Wilson's disease, progressive familial intrahepatic cholestasis type 2 (PFIC2), progressive familial intrahepatic cholestasis type 3 (PFIC3) and citrullinemia type I, the company said in a statement.

Vivet will mostly continue research for its lead product VTX801 targeting Wilson's disease. The disease affects approximately one in 30,000 people worldwide, including 10,000 patients in the US and 15,000 patients in the EU. Vivet expects to start human trials with VTX801 by the end of 2018.

Company
Created in 2016, Vivet is a biotechnology company developing gene therapy treatments for rare, inherited metabolic diseases. Founded by sector specialists Jens Kurth (formerly at Anokion and Novartis), Gloria Gonzalez Aseguinolaza, and Jean-Philippe Combal (formerly at Gensight Biologics and Sanofi), the group also owns a subsidiary in Spain.

People
Novartis Venture Fund – Florent Gros (managing director).
Vivet Therapeutics – Gloria Gonzalez Aseguinolaza (co-founder/CSO); Jean-Philippe Combal (co-founder/CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• France
• France
• Venture